|
[1] DA BL, KOH C, HELLER T. Non-cirrhotic portal hypertension[J]. Curr Opin Gastroenterol, 2018, 34 (3) :140-145.
|
|
[2] FAN CQ, CRAWFORD LM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease) [J]. J Clin Exp Hepatol, 2014, 4 (4) :332-346.
|
|
[3] WANG X, QI X, GUO X. Tusanqi-related sinusoidal obstruction syndrome in China:A systematic review of the literatures[J]. Medicine (Baltimore) , 2015, 94 (23) :e942.
|
|
[4] ZHANG JF, LIU B, CHEN CX. Increased chal enge in traditional Chinese medicine containing pyrrolizidine alkaloids-induced hepatic sinusoidal ob-struction syndrome[J]. J Pract Hepatol, 2014, 17 (4) :445-448. (in Chinese) 张骏飞, 刘波, 陈从新.含吡咯烷生物碱的中草药致肝窦阻塞综合征研究进展[J].实用肝脏病杂志, 2014, 17 (4) :445-448
|
|
[5] VIGANO L, CAPUSSOTTI L, de ROSA G, et al. Liver resection for colorectal metastases after chemotherapy:Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J]. Ann Surg, 2013, 258 (5) :731-740.
|
|
[6] NGUYEN-KHAC E, LOBRY C, CHATELAIN D, et al. A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics[J]. Int J Hepatol, 2013, 2013:314868.
|
|
[7] HUBERT C, SEMPOUX C, HUMBLET Y, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases:Factors predictive of severe SOS lesions and protective effect of bevacizumab[J]. HPB (Oxford) , 2013, 15 (11) :858-864.
|
|
[8] VREULS CP, OLDE DAMINK SW, KOEK GH, et al. Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer[J]. Br J Cancer, 2013, 108 (3) :676-680.
|
|
[9] TALLMAN MS, MCDONALD GB, DELEVE LD, et al. Incidence of sinusoidal obstruction syndrome fol owing Mylotarg (gemtuzumab ozogamicin) :A prospective observational study of 482 patients in routine clinical practice[J]. Int J Hematol, 2013, 97 (4) :456-464.
|
|
[10] MARZANO C, CAZALS-HATEM D, RAUTOU PE, et al. The sig-nificance of nonobstructive sinusoidal dilatation of the liver:Impaired portal perfusion or inflammatory reaction syndrome[J]. Hepatology, 2015, 62 (3) :956-963.
|
|
[11] TAKAMURA H, NAKANUMA S, HAYASHI H, et al. Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation[J].Transplant Proc, 2014, 46 (10) :3523-3535.
|
|
[12] MOHTY M, MALARD F, ABECASSIS M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease:Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) [J]. Bone Marrow Transplant, 2015, 50 (6) :781-789.
|
|
[13] SEIFERT C, WITTIG S, ARNDT C, et al. Heparanase polymorphisms:influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation[J]. J Cancer Res Clin Oncol, 2015, 141 (5) :877-885.
|
|
[14] EFRATI E, ZUCKERMAN T, BEN-AMI E, et al. MTHFR C677T/A1298C genotype:A possible risk factor for liver sinusoidal obstruction syndrome[J]. Bone Marrow Transplant, 2014, 49 (5) :726-727.
|
|
[15] ROBINSON S, MANN J, VASILAKI A, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model[J]. J Hepatol, 2013, 59 (2) :318-326.
|
|
[16] ROBINSON S, MANN D, MANAS D, et al. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J]. Br J Cancer, 2013, 109 (9) :2396-2403.
|
|
[17] EDGAR JA, MOLYNEUX RJ, COLEGATE SM. Pyrrolizidine alkaloids:potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease[J].Chem Res Toxicol, 2015, 28 (1) :4-20.
|
|
[18] VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40 (4) :378-385.
|
|
[19] CHAO N. How I treat sinusoidal obstruction syndrome[J].Blood, 2014, 123 (26) :4023-4026.
|
|
[20] GAO H, RUAN JQ, CHEN J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome[J]. Drug Des Devel Ther, 2015, 9:4861-4868.
|
|
[21] LEE JH. Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation[J]. Blood Res, 2015, 50 (3) :123-125.
|
|
[22] SHAO H, CHEN HZ, ZHU JS, et al. Computed tomography findings of hepatic veno-occlusive disease caused by Sedumaizoon with histopathological correlation[J]. Braz J Med Biol Res, 2015, 48 (12) :1145-1150.
|
|
[23] RICHARDSON PG, TRIPLETT BM, HO VT, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Expert Rev Clin Pharmacol, 2018, 11 (2) :113-124.
|
|
[24] HOPPS SA, BORDERS EB, HAGEMANN TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:A review of the literature[J]. J Oncol Pharm Practice, 2016, 22 (3) :496-510.
|
|
[25] YOON JH, MIN WS, KIM HJ, et al. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT:Is it still reasonable to use t-PA?[J]. Bone Marrow Transplant, 2013, 48 (12) :1562-1568.
|
|
[26] DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline:Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163 (4) :444-457.
|
|
[27] MYERS KC, LAWRENCE J, MARSH RR, et al. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients[J]. Biol Blood Marrow Transplant, 2013, 19 (3) :492-503.
|
|
[28] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.
|
|
[29] SCHWABL P, HAMBRUCH E, SEELAND BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular re-modelling and sinusoidal dysfunction[J]. J Hepatol, 2017, 66 (4) :724-733.
|
|
[30] RASZEJA-WYSZOMIRSKA J, WASILEWICZ M, ANDRZEJEWSKA A, et al. Orthotopic liver transplantation (OLTx) in non-cirrhotic portal hypertension secondary to ADAMTS13 deficiency[J]. Prz Gastroenterol, 2016, 11 (1) :56-58.
|
|
[31] HOPPS SA, BORDERS EB, HAGEMANN TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:A review of the literature[J]. J Oncol Pharm Practice, 2016, 22 (3) :496-510.
|
|
[32] BARGE S, GRANDO V, NAULT JC, et al. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies[J]. Liver Int, 2016, 36 (7) :1059-1066.
|
|
[33] JHARAP B, van ASSELDONK DP, de BOER NKH, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low inter-observer agreement[J]. PLoS One, 2015, 10 (6) :e0120299.
|
|
[34] MEIJER B, SIMSEK M, BLOKZIJL H, et al. Nodular regenerative hyperplasia rarely leads to liver transplantation:A 20-year cohort study in all Dutch liver transplant units[J]. Unit Eur Gastroenterol J, 2017, 5 (5) :658-667.
|
DownLoad: